|
Aug 7
|
InflaRx N.V. (IFRX) Reports Q2 Loss, Misses Revenue Estimates
|
|
Aug 7
|
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Jul 31
|
Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
|
|
Jul 31
|
InflaRx to Report Second Quarter 2025 Results on August 7, 2025
|
|
Jul 25
|
InflaRx Discontinues Pyoderma Gangrenosum Trial, Shifts Focus to INF904 with Summer 2025 Data Expected
|
|
May 22
|
InflaRx to Participate in Upcoming Investor Conferences
|
|
Feb 18
|
InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jan 23
|
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
|
|
Jan 16
|
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS
|
|
Jan 16
|
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug
|
|
Jan 15
|
InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
|
|
Jan 7
|
InflaRx Announces Participation in January Events in San Francisco
|